Stimulation of triglyceride breakdown through exogenous supplementation of pancreatic enzymes normalizes lipid-induced GIP secretion in people with cystic fibrosis [339], and, conversely, treatment with the lipase inhibitor orlistat decreases meal-induced GIP secretion in healthy humans [374] and in individuals with T2D [375]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.